Market revenue for the North America Ophthalmology Drugs & Devices sector is projected to experience consistent growth from 2020 through 2035. In 2021, revenue stood at 13,800 million, rising to 18,900 million by 2025 on the strength of growing demand for advanced treatments and technology adoption. The market is further forecasted to expand, reaching 27,400 million by 2030 and surpassing 37,200 million in 2035. This positive trajectory is fueled by advances in surgical devices, targeted therapies, and demographic shifts such as an increasingly aging population. The upward revenue trend underlines the sector's robust ecosystem and continued investments in next-generation diagnostic and treatment solutions.
Read More - https://bussinessinsights.com/research-report/north-america-ophthalmology-drugs-and-devices-market
By application, cataract treatments hold the largest share of the North American market at 34%, driven primarily by the aging baby boomer population and the prevalent use of phacoemulsification technology. Glaucoma therapies follow at 26% as heightened screening initiatives and minimally invasive therapies (MIGS) gain traction. Treatments for refractive errors capture a 21% market share, catalyzed by increased consumer interest in LASIK and corrective lens implants. The remaining 19% covers age-related macular degeneration, diabetic retinopathy, and other ophthalmic conditions. Rapid uptake of innovative approaches, such as anti-VEGF injections and digital retina imaging, has contributed to robust growth in all segments. This diversified application landscape affords resilience and maintains demand, even as healthcare delivery models evolve towards telemedicine and ambulatory care.
Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-ophthalmology-drugs-and-devices-market
Who are the key players in North America Ophthalmology Drugs & Devices Market industry?
The key players include Alcon Inc., Johnson & Johnson, Bausch Health Companies, Novartis AG, and Abbott Laboratories. These leading companies dominate the market by offering a wide range of innovative ophthalmic drugs and devices, substantial R&D investments, and extensive distribution networks across the North American region.
What is the North America Ophthalmology Drugs & Devices Market growth?
The North America Ophthalmology Drugs & Devices Market has seen robust growth, driven by increasing prevalence of eye diseases and technological advancements. For instance, Johnson & Johnson has recently expanded its portfolio with advanced intraocular lenses, propelling overall market growth at a CAGR of around 5.5% in recent years.
Which segment accounted for the largest North America Ophthalmology Drugs & Devices Market share?
Surgical devices segment holds the largest market share, attributed to the high demand for cataract and refractive surgeries. Increasing adoption of minimally invasive procedures and advanced phacoemulsification systems, coupled with a growing geriatric population, have further reinforced the market dominance of surgical applications.
Thanks & Regards,
Manisha C
sales [at] bussinessinsights.com